Director Discretionary Decision: Refer | Jul 31, 2025 | PAPER | BOARD |
Patent Owner's Preliminary Response | Jul 15, 2025 | PAPER | PATENT OWNER |
EGFR expression in normal human tissues | Jul 15, 2025 | EXHIBIT | PATENT OWNER |
CD30 expression in normal human tissues | Jul 15, 2025 | EXHIBIT | PATENT OWNER |
EP4434549A1 | Jul 15, 2025 | EXHIBIT | PATENT OWNER |
CSPC Announcement | Jul 15, 2025 | EXHIBIT | PATENT OWNER |
First-in-human study of SYS6010 | Jul 15, 2025 | EXHIBIT | PATENT OWNER |
WO2012100346A1 | Jul 15, 2025 | EXHIBIT | PATENT OWNER |
Preclinical evaluation of HTI-1511 | Jul 15, 2025 | EXHIBIT | PATENT OWNER |
Characterization of ABBV-221 | Jul 15, 2025 | EXHIBIT | PATENT OWNER |
Phase I study of ABBV-321 | Jul 15, 2025 | EXHIBIT | PATENT OWNER |
US20110076232A1 | Jul 15, 2025 | EXHIBIT | PATENT OWNER |
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 | Jul 15, 2025 | EXHIBIT | PATENT OWNER |
Lepu Biopharma Co. Ltd. 2024 Annual Report | Jul 15, 2025 | EXHIBIT | PATENT OWNER |
Written Opinion of the International Searching Authority for WO2023088382 | Jul 15, 2025 | EXHIBIT | PATENT OWNER |
CSPC Pharmaceutical Group Ltd. Voluntary Announcement, May 19, 2025 | Jul 7, 2025 | EXHIBIT | PETITIONER |
Study of SYS6010 and Platinum-based Chemotherapy in Patients with EGFR-mutated NSCLC, April 15, 2025 | Jul 7, 2025 | EXHIBIT | PETITIONER |
Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors | Jul 7, 2025 | EXHIBIT | PETITIONER |
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors. Cancer.gov | Jul 7, 2025 | EXHIBIT | PETITIONER |
Petitioners' Response to Patent Owner's Request for Discretionary Denial of Institution | Jul 7, 2025 | PAPER | PETITIONER |
Patent Owner's Request for Discretionary Denial | Jun 6, 2025 | PAPER | PATENT OWNER |
International Nonproprietary Names for Pharmaceutical Substances | Jun 6, 2025 | EXHIBIT | PATENT OWNER |
Han et al. Becotatug Vedotin vs. Chemotherapy | Jun 6, 2025 | EXHIBIT | PATENT OWNER |
Lepu Biopharma Voluntary Announcement Regarding MRG003 | Jun 6, 2025 | EXHIBIT | PATENT OWNER |
Fast Track _ FDA | Jun 6, 2025 | EXHIBIT | PATENT OWNER |
Breakthrough Therapy _ FDA | Jun 6, 2025 | EXHIBIT | PATENT OWNER |
Notice: Notice filing date accorded | Apr 15, 2025 | PAPER | BOARD |
Patent Owner's Mandatory Notice | Mar 21, 2025 | PAPER | PATENT OWNER |
Patent Owner's Power of Attorney | Mar 21, 2025 | PAPER | PATENT OWNER |
U.S. Patent No. 10,792,370 to Hu (“the ’370 patent”) | Mar 3, 2025 | EXHIBIT | PETITIONER |
File History of U.S. Patent No. 10,792,370 Part 1 | Mar 3, 2025 | EXHIBIT | PETITIONER |
File History of U.S. Patent No. 10,792,370 Part 2 | Mar 3, 2025 | EXHIBIT | PETITIONER |
U.S. Patent Application Publication No. US 2015/071923 (“Wei”) | Mar 3, 2025 | EXHIBIT | PETITIONER |
International Publication No. WO 2014/152199 (“Leanna”) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Chinese Patent Application Publication No. CN103772504 (“Liu”) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Certified English Translation of Chinese Patent App. Pub. No. CN103772504 | Mar 3, 2025 | EXHIBIT | PETITIONER |
International Publication No. WO 2015/000062 (“Tikhomirov”) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Metrangolo & Engelholm, Cancers (Basel), 16(2):447 (2024) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Tsurushita, et al., Methods., 36(1):69-83 (2005) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Jorissen, et al., Exp Cell Res., 284(1):31-53 (2003) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Olayioye, et al., EMBO J., 19(13):3159-67 (2000) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Bou-Assaly & Mukherji, AJNR Am J Neuroradiol., 31(4):626-7 (2010) | Mar 3, 2025 | EXHIBIT | PETITIONER |
McCombs & Owen, AAPS J., 17(2):339-51 (2015) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Kovtun & Goldmacher, Cancer Lett., 255(2):232-40 (2007) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Okeley, et al., Clin Cancer Res., 16(3):888-97 (2010) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Nagaria, et al., Neoplasia,15(8):939-51 (2013) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Perez, et al., Drug Discovery Today, 19(7): 869-881 (2014) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Alley, et al., Curr Opin Chem Biol., 14(4):529-37 (2010) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Younes, et al., Nat Rev Drug Discov., 11(1):19-20 (2012) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Hwang & Foote, Methods., 36(1):3-10 (2005) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Herbst & Shin, Cancer., 94(5):1593-611 (2002) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Martinelli, et al., Clin Exp Immunol., 158(1):1-9 (2009) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Atalay, et al., Ann Oncol., 14(9):1346-63 (2003) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Doronina, et al., Nat Biotechnol., 21(7):778–784 (2003) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Mao, et al., Cancer Res., 64 (3): 781–788 (2004) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Afar, et al., Mol Cancer Ther., 3(8):921-32 (2004) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Doronina, et al., Bioconjug Chem., 17(1):114-24 (2006) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Chinese Patent Application No. 201510085038.8 (“the ’038.8 Provisional”) | Mar 3, 2025 | EXHIBIT | PETITIONER |
De Goeij, et al., Mol Cancer Ther., 14(5):1130-40 (2015) | Mar 3, 2025 | EXHIBIT | PETITIONER |
U.S. Patent No. 9,493,568 to Reilly, et al. | Mar 3, 2025 | EXHIBIT | PETITIONER |
Khan, et al., World J Gastroenterol., 20(11):2979-94 (2014) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Foltz, et al., Circulation., 127(22):2222-30 (2013) | Mar 3, 2025 | EXHIBIT | PETITIONER |
Certified English Translation of Chinese Patent App. No. 201510085038.8 | Mar 3, 2025 | EXHIBIT | PETITIONER |
Declaration of Stylianos Bournazos, Ph.D. | Mar 3, 2025 | EXHIBIT | PETITIONER |
Petition: as filed | Mar 3, 2025 | PAPER | PETITIONER |
Notice: Power of Attorney | Mar 3, 2025 | PAPER | PETITIONER |